Related Experiment Video
Updated: Jul 19, 2026
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Gene therapy for chronic granulomatous disease
Stefan Stein1, Ulrich Siler, Marion G Ott
1Institute for Biomedical Research, Georg-Speyer-Haus, Paul-Ehrlich-Strasse 42-44, 60596 Frankfurt, Germany.
Current Opinion in Molecular Therapeutics
|November 3, 2006
Summary
Gene therapy offers a potential cure for Chronic Granulomatous Disease (CGD), a rare immunodeficiency. This approach genetically modifies a patient's own stem cells, providing a treatment option when bone marrow transplants are unavailable.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- Chronic Granulomatous Disease (CGD) is a rare inherited immunodeficiency.
- It causes life-threatening bacterial and fungal infections due to defective neutrophil microbial-killing activity.
- Conventional treatments and bone marrow transplants are limited by donor availability.
Purpose of the Study:
- To review the developments in gene therapy for CGD.
- To highlight gene therapy as an alternative for patients lacking suitable bone marrow donors.
- To discuss the successful correction of CGD through genetic modification of hematopoietic stem cells.
Main Methods:
- Review of scientific literature on gene therapy for CGD.
- Focus on genetic modification of autologous hematopoietic stem cells.
- Analysis of advancements leading to successful CGD correction protocols.
Main Results:
- Gene therapy has emerged as a viable therapeutic option for CGD.
- Successful correction of the functional defect in CGD patients' cells.
- Overcoming limitations associated with traditional bone marrow transplantation.
Conclusions:
- Gene therapy represents a significant breakthrough for treating CGD.
- It provides a personalized treatment strategy for patients without matched donors.
- Further developments in gene therapy hold promise for managing inherited immunodeficiencies.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:32Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...